World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
55
Citations
10562
World Ranking
3807
National Ranking
1746

Mark A. Tomai publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mark A. Tomai sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 123 publications — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Mark A. Tomai D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mark A. Tomai sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 55 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Mark A. Tomai is affiliated with 3M in the United States. Their research primarily focuses on fields related to medicine, immunology, and microbiology. Within these broad areas, their work extensively covers subfields including immunology, infectious diseases, virology, epidemiology, and molecular biology.

The main topics explored in their research include:

  • SARS-CoV-2 and COVID-19 Research
  • HIV Research and Treatment
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • T-cell and B-cell Immunology
  • Vaccines and Immunoinformatics Approaches
  • Immune Response and Inflammation

Mark A. Tomai has published extensively in notable venues. Frequent publication venues for their work include:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature Communications
  • Science Immunology
  • Science Translational Medicine
  • Frontiers in Immunology

Recent significant papers authored or coauthored by Mark A. Tomai include:

  • New horizons in adjuvants for vaccine development (2020, Current Opinion in Immunology)
  • Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses (2021, Nature)
  • T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers (2020, Nature Medicine)
  • 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates (2020, Science Immunology)
  • SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung (2021, Nature Communications)

Mark A. Tomai collaborates frequently with a group of coauthors who contribute to related research fields. Notable frequent coauthors include:

  • Christopher B. Fox
  • David C. Montefiori
  • Barton F. Haynes
  • Kevin O. Saunders
  • Ralph S. Baric

Best Publications

  • Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

    Keith B. Gorden;Kevin S. Gorski;Sheila J. Gibson;Ross M. Kedl

  • Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

    Sheila J Gibson;Jana M Lindh;Tony R Riter;Raymond M Gleason

  • Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

    Unknown

  • A Randomized, Controlled, Molecular Study of Condylomata Acuminata Clearance during Treatment with Imiquimod

    Stephen K. Tyring;Istvan Arany;Margaret A. Stanley;Mark A. Tomai

  • Cytokine induction by the immunomodulators imiquimod and S-27609.

    Traci L. Testerman;John F. Gerster;Linda M. Imbertson;Michael J. Reiter

  • Development of a Topically Active Imiquimod Formulation

    John L. Chollet;Michael J. Jozwiakowski;Kenneth R. Phares;Michael J. Reiter

  • The use of Toll-like receptor 7/8 agonists as vaccine adjuvants

    John P Vasilakos;Mark A Tomai

  • Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.

    Kevin O. Saunders;Esther Lee;Robert Parks;David R. Martinez

  • Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.

    John P. Vasilakos;Rose M.A. Smith;Sheila J. Gibson;Jana M. Lindh

  • Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways.

    K Megyeri;W C Au;I Rosztoczy;N B Raj

  • The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells.

    Robert P. Burns;Barbara Ferbel;Mark Tomai;Richard Miller

  • The antiviral activity of Toll-like receptor 7 and 7/8 agonists.

    Richard L Miller;Tze-Chiang Meng;Mark A Tomai

  • Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists

    Kevin S. Gorski;Emily L. Waller;Jacqueline Bjornton-Severson;John A. Hanten

  • Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

    Stefanie R. Mullins;John P. Vasilakos;Katharina Deschler;Iwen Grigsby

  • The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes.

    Mark A. Tomai;Linda M. Imbertson;Tamara L. Stanczak;Lorraine T. Tygrett

  • Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules

    Mark A. Tomai;John P. Vasilakos;John C. Stolpa

  • Targeted selection of HIV-specific antibody mutations by engineering B cell maturation.

    Kevin O. Saunders;Kevin Wiehe;Ming Tian;Priyamvada Acharya

  • Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848.

    Cory L. Ahonen;Sheila J. Gibson;Rose M. Smith;Linda K. Pederson

  • Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609

    Sheila J. Gibson;Linda M. Imbertson;Tamara L. Wagner;Traci L. Testerman

  • Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5

    Istvan Arany;Stephen K Tyring;Margaret A Stanley;Mark A Tomai

  • T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.

    Prabhu S. Arunachalam;Tysheena P. Charles;Vineet Joag;Venkata S. Bollimpelli

  • Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells

    D E Spaner;Y Shi;D White;J Mena

  • Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment.

    David I. Bernstein;Christopher J. Harrison;Mark A. Tomai;Richard L Miller

  • Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1–dependent pathways

    Victoria J. Philbin;Victoria J. Philbin;David J. Dowling;David J. Dowling;Leighanne C. Gallington;Guadalupe Cortés;Guadalupe Cortés

  • TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth

    David J. Dowling;David J. Dowling;Simon D. van Haren;Simon D. van Haren;Annette Scheid;Ilana Bergelson

  • 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates

    Sudhir Pai Kasturi;Mohammed Ata Ur Rasheed;Mohammed Ata Ur Rasheed;Colin Havenar-Daughton;Mathew Pham

  • Characterization of a Nontoxic Monophosphoryl Lipid A

    Arthur G Johnson;M. Tomai;L. Solem;L. Beck

  • Methods and compositions for enhancing immune response

    Richard L. Miller;Mark A. Tomai;Ross M. Kedl;Isidro Angelo Eleazar Zarraga

  • Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands.

    Jeffrey A. Martinson;Alejandro Roman-Gonzalez;Allan R. Tenorio;Carlos J. Montoya

  • A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.

    Neal Van Hoeven;Christopher B Fox;Brian Granger;Tara Evers

  • SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung.

    Nanda Kishore Routhu;Narayanaiah Cheedarla;Venkata Satish Bollimpelli;Sailaja Gangadhara

  • Immunostimulatory combinations and treatments

    Ross M Kedl;Mark A Tomai;John P Vasilakos

  • New horizons in adjuvants for vaccine development.

    Steven G Reed;Mark Tomai;Michael J Gale

Frequent Co-Authors

Ross M. Kedl
Ross M. Kedl University of Colorado Boulder
Ofer Levy
Ofer Levy Boston Children's Hospital
Maria Wysocka
Maria Wysocka University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can broaden career opportunities in clinical and research fields. Many professionals start with nursing credentials before specializing further. Online options make it easier for non-traditional students to enter the field quickly.

Programs like accelerated nurse practitioner programs provide a fast-track route for those with prior degrees to become advanced practice nurses, often blending clinical immunology knowledge into their studies.

For beginners without a healthcare background, the best online RN programs for non nurses offer flexible pathways to gain foundational nursing skills, essential for immunology-related roles in hospitals or labs.

If you're looking for a quicker entry point, consider accelerated BSN programs for non nurses, which allow students to obtain a Bachelor of Science in Nursing efficiently and start contributing to immunology care teams sooner.

Many also start with supporting roles via easy LPN programs to get into, providing essential practical experience that can lead to advanced studies and roles in immunological healthcare settings.

Best Scientists Citing Mark A. Tomai

Trending Scientists

Recently Published Articles